Form D · Biotechnology

Temple Therapeutics Holdings Ltd

Geleen, P7 · CIK 0001896459

Offering snapshot reported Dec 26, 2023 · SEC filing

Reported sold
$200K
Offering amount: $3.5M
Investors reported
5
Form D · investor count
Minimum accepted
$25K
Reported outside-investor minimum
First sale
Oct 26, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 26, 2023Initial$200,000No comparison5SEC filing
Dec 26, 2023Initial$25,000No comparison1SEC filing
Dec 26, 2023Initial$100,000No comparison1SEC filing
May 27, 2022Initial$600,000No comparison3SEC filing
May 27, 2022Initial$350,000No comparison4SEC filing
Jan 3, 2022Initial$150,000No comparison3SEC filing
Dec 9, 2021Initial$300,000No comparison3SEC filing

Offering details

Securities
Debt
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$150K (estimated)
Finders' fees
$0
Form D file number
021-500708
The reported sales commissions fee is equal to 3.0% of the total amount sold in the offering.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
TerraNova Capital Equities, lnc.45097

Source: Form D, filed Dec 26, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Sanj Singh Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
Urmonderbaan 22, Gate 2
Geleen, P7, 6167 RD